FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Volker Heinemann(LMU Klinikum), Sebastian Stintzing(Humboldt-Universität zu Berlin), Alexander Kiani(Bayreuth Medical Center), Thomas Decker, Markus Moehler(Johannes Gutenberg University Mainz), Dominik Paul Modest(Berliner Hochschule für Technik), Christoph Lerchenmüller, Swantje Held(AIO Studien gGmbH), Andreas Jung(Ludwig-Maximilians-Universität München), Christoph Kahl(Klinikum Magdeburg), Tobias Heintges(Lukaskrankenhaus), Florian Kaiser(University of Applied Sciences Landshut), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Werner Scheithauer(Comprehensive Cancer Center Vienna), G. Seipelt, Frank Kullmann(Klinikum Weiden), Lisa Miller‐Phillips(Ludwig-Maximilians-Universität München), Salah-Edin Al-Batran(Goethe University Frankfurt), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 187
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k